The Life Sciences team advised BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) on its registered direct offering of 4,054,055 shares of common stock and warrants to purchase up to an aggregate of 4,054,055 shares of common stock. Each share of common stock was offered together with a warrant to purchase one share of common stock at a combined purchase price of $1.85 per share. The warrants have an exercise price of $2.00 per share, will be immediately exercisable and will expire five years from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $7.5 million. The offering closed on July 19, 2023.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
The Goodwin team was led by Mayan Katz, Della Fok, Karin Yoo and Haylee Brown, with assistance from Brad Weber.
For more details, read the press release.